Thomas Stinchcombe, MD
Duke University · University of North Carolina, Chapel Hill · North Carolina Cancer Hospital at University of NC at Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Stinchcombe, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04099836 · Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibDuke University · terminated · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT03434418 · A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsDuke University · completed · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT02963090 · Pembrolizumab vs Topotecan in Patients With Small Cell Lung CancerAlliance Foundation Trials, LLC. · terminated · Small Cell Lung Cancer · study chair
- Ph2NCT02706626 · Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsCriterium, Inc. · terminated · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT01262820 · Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing BevacizumabUNC Lineberger Comprehensive Cancer Center · completed · Lung Cancer · principal investigator
- Ph2NCT00454324 · Study of Abraxane and Carboplatin to Treat Small Cell Lung CancerUNC Lineberger Comprehensive Cancer Center · terminated · Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT00280150 · Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung CancerUNC Lineberger Comprehensive Cancer Center · completed · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.